




**BIOMATRIX**  
DRUG ELUTING CORONARY  
STENT SYSTEM *NEOFLEX*™

Raising the standard in deliverability



**BIOMATRIX**  
DRUG ELUTING CORONARY  
STENT SYSTEM *NEOFLEX*™

Raising the standard in deliverability



### Ordering Information

Stent Diameter (mm)	Stent Length (mm)							
	8	11	14	18	24	28	33	36
2.25	BMXP-2208	BMXP-2211	BMXP-2214	BMXP-2218	BMXP-2224	BMXP-2228	NA	NA
2.50	BMXP-2508	BMXP-2511	BMXP-2514	BMXP-2518	BMXP-2524	BMXP-2528	BMXP-2533	BMXP-2536
2.75	BMXP-2708	BMXP-2711	BMXP-2714	BMXP-2718	BMXP-2724	BMXP-2728	BMXP-2733	BMXP-2736
3.00	BMXP-3008	BMXP-3011	BMXP-3014	BMXP-3018	BMXP-3024	BMXP-3028	BMXP-3033	BMXP-3036
3.50	BMXP-3508	BMXP-3511	BMXP-3514	BMXP-3518	BMXP-3524	BMXP-3528	BMXP-3533	BMXP-3536
4.00	BMXP-4008	BMXP-4011	BMXP-4014	BMXP-4018	BMXP-4024	BMXP-4028	NA	NA

\* In vivo testing in porcine model demonstrates abluminal coating is absorbed after 6 to 9 months – Data on file at Biosensors International

1. LEADERS is a Biosensors International study. [www.clinicaltrials.gov](http://www.clinicaltrials.gov) - NCT00389220
2. P. W. Serruys, LEADERS: 5-year follow-up from a prospective, randomized trial of Biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer, oral abstract presentation, TCT 2012
3. Data on file at Biosensors International

BioMatrix NeoFlex™ drug eluting stent system is CE approved.

Biosensors International Group, Ltd. licenses its proprietary BA9™ drug and PLA technology to Terumo Corporation (Nobori®). The BioMatrix NeoFlex™ stent is indicated in diabetics, STEMI and ACS patients for stent lengths up to 28 mm. LEADERS is a Biosensors International study. [www.clinicaltrials.gov](http://www.clinicaltrials.gov) - NCT00389220.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix NeoFlex, BioMatrix Flex, Juno, Quadrature Link, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries. All cited trademarks are the property of their respective owners.

**Not available for sale in the United States and certain other countries.**

© 2013 Biosensors International Group, Ltd. All rights reserved

[www.biosensors.com](http://www.biosensors.com)

**BIOSENSORS**  
INTERNATIONAL™

**BIOSENSORS EUROPE SA**

Rue de Lausanne 29  
1110 Morges  
Switzerland  
Tel: +41 (0)21 804 80 00  
Fax: +41 (0)21 804 80 01

**BIOSENSORS INTERVENTIONAL  
TECHNOLOGIES PTE LTD**

Blk 10 Kaki Bukit Avenue 1  
#06-01/04  
Singapore 417942  
Tel: +65 6213 5725  
Fax: +65 6213 5737

11184-000PH - Rev 01

**BIOSENSORS**  
INTERNATIONAL™

# BioMatrix NeoFlex™: Exceptional performance – Premium deliverability



Biosensors brings you the newest member of the BioMatrix™ family: BioMatrix NeoFlex.

With the LEADERS<sup>1</sup> trial 5-year results BioMatrix Flex™ achieved Gold Standard status in biodegradable technology.

Now BioMatrix NeoFlex with an enhanced stent delivery system, brings exceptional performance in complex lesions and challenging anatomy.

## BioMatrix NeoFlex: one step beyond

When it comes to biodegradable polymer technology, Biosensors has developed the highest level of expertise and delivered the best results in terms of safety and efficacy, as demonstrated by the landmark LEADERS<sup>2</sup> trial. The additional improvement with NeoFlex is provided by an even better delivery system.



## Proven efficacy of the Biolimus A9 drug

BA9 differs from common limus drugs by having increased lipophilicity properties. BA9 lipophilicity offers improved characteristics for a drug intended for local action on vascular SMC, including rapid transfer to cells in the vessel wall coupled with limited systemic exposure.

